PRESS DIGEST- Financial Times - March 27
March 27 The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy.
March 9 Endo International Plc
* FDA staff: postmarketing data suggests opana er reformulation likely reduced nasal abuse rates, but data limitations makes it hard to determine magnitude of effect
* FDA staff: postmarketing data indicate an increase in opana er injection abuse rates over the study period
* FDA staff: the data are difficult to interpret with regard to the impact of opana er’s reformulation on overall abuse of the drug (via any route). Source text for Eikon: (bit.ly/2m62jla) Further company coverage:
HONG KONG, March 27 Asian stocks are set to start the week on a cautious note as President Donald Trump's stunning failure to get healthcare reform passed raised concerns about the prospects for his plans to use fiscal stimulus to boost economic growth.